Women's Health

Smoking drives lung cancer deaths, but race predicts breast/prostate mortality. New study reveals distinct community factors for each cancer type's outcomes.

Common questions on the critical window hypothesis for timing of postmenopausal MHT ask about rationale, clinical evidence, and guideline response.

Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.

Menopause specialist Caroline Mitchell, MD, MPH, explains the dual nature of the breakdown in communication that can leave women virtually uninformed about GSM and treatment.

The phase 3 E4COMFORT II trial found no impact on BP after 1 year of treatment in postmenopausal women with elevated HbA1c, lipids, and TGs.

TMS: Half of postmenopausal women suffer from GSM, yet only 25% seek treatment. Mitchell, an expert in vulvovaginal health, explains the gap and its impact on women.

The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.

Our short slide show outlines interrelated syndromes of menopause across 13 body systems, implicating therapeutic targets and approaches for clinical practice.

Subtle sleep, mood, and cycle changes may herald perimenopause. Dr. Marla Shapiro discusses how clinicians can recognize and address them early.

Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.

A secondary analysis of the ELITE trial suggests that there may be a postmenopausal "critical window" during which use of MHT is optimal.

Only 3% of physician associate respondents reported receiving more than 5 hours of menopause-related training during their professional education.

TMS 2025: Katrina Wugalter, MA, explains why treating vasomotor symptoms may be key to improving cognitive function during menopause.

Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.

TMS: Menopause care isn’t one-size-fits-all—and that’s the problem. Wake Forest data reveal deep disparities in who gets treated and how.

TMS 2025: Donna Plecha, MD, an expert in breast imaging, discusses essential breast cancer screening recommendations for primary care physicians.

TMS: New preliminary data show reduction in bothersome VMS as early as week 4, an effect that led to statistically significant improvements across other life domains.

TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.

TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.

TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.

TMS: Findings from a large study presented at TMS 2025 counter previous reports suggesting menopause-specific effects on brain structure at midlife.

Your daily dose of the clinical news you may have missed.

New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.

TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.